Adult-onset Still’s Disease
Jul 01, 2025
Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis
FDA Approves Sobi’s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still’s Disease In a major advancement for rare inflammatory conditions, the FDA has approved GAMIFANT (emapalumab-lzsg) for the treatment of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MA...
Read More...
May 31, 2021
Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market
Adult-onset Still’s Disease (AoSD), alternatively known as systemic-onset juvenile idiopathic arthritis, is a rare systemic inflammatory disorder of unknown etiology. There are three main patterns of AoSD’s clinical course: monophasic, intermittent, and chronic. Although there is an approximately equal distri...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
